Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Research & Development (2016 - 2022)

Historic Research & Development for Collegium Pharmaceutical (COLL) over the last 7 years, with Q1 2022 value amounting to $4.0 million.

  • Collegium Pharmaceutical's Research & Development rose 3593.86% to $4.0 million in Q1 2022 from the same period last year, while for Dec 2022 it was $4.0 million, marking a year-over-year decrease of 5785.63%. This contributed to the annual value of $4.0 million for FY2022, which is 5785.63% down from last year.
  • Latest data reveals that Collegium Pharmaceutical reported Research & Development of $4.0 million as of Q1 2022, which was up 3593.86% from $1.6 million recorded in Q4 2021.
  • Over the past 5 years, Collegium Pharmaceutical's Research & Development peaked at $4.0 million during Q1 2022, and registered a low of $1.4 million during Q3 2021.
  • Its 5-year average for Research & Development is $2.5 million, with a median of $2.5 million in 2019.
  • Over the last 5 years, Collegium Pharmaceutical's Research & Development had its largest YoY gain of 3886.88% in 2021, and its largest YoY loss of 3491.1% in 2021.
  • Over the past 5 years, Collegium Pharmaceutical's Research & Development (Quarter) stood at $2.2 million in 2018, then grew by 6.63% to $2.4 million in 2019, then increased by 3.09% to $2.5 million in 2020, then tumbled by 34.91% to $1.6 million in 2021, then soared by 147.55% to $4.0 million in 2022.
  • Its Research & Development stands at $4.0 million for Q1 2022, versus $1.6 million for Q4 2021 and $1.4 million for Q3 2021.